INOVIQ Ltd (FRA:EGQ0)

Germany · Delayed Price · Currency is EUR

0.0760

+0.0030 (4.11%)

Last updated: Oct 23, 2026, 8:06 AM CEST

Market Cap	12.38M -53.8%
Revenue (ttm)	1.34M +22.0%
Net Income	-4.54M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Open	0.0760
Previous Close	0.0730
Day's Range	0.0760 - 0.0760
52-Week Range	0.0725 - 0.3140
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 17, 2026

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an immunoaffinity magnetic bead-based isolation system for exosome isolation from plasma, serum, urine, saliva and cell-conditioned medium. It also offers non-invasive diagnostics using its proprietary exosome development technologies fo... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2016

Employees 15

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol EGQ0

Financial Performance

In fiscal year 2026, INOVIQ's revenue was 2.21 million, an increase of 21.98% compared to the previous year's 1.82 million. Losses were -7.51 million, 8.26% more than in 2025.

Financial numbers in AUD Financial Statements